Biomarker Development for Alzheimer's Disease Diagnostics

Alzheimer’s disease is defined by a progressive accumulation of misfolded proteins and neuronal loss that often predates clinical symptoms by years. Biomarkers aim to detect pathological hallmarks such as amyloid-β plaques and tau tangles, to stratify individuals at risk, monitor disease progression and evaluate therapeutic interventions. Initially confined to cerebrospinal fluid measures of Aβ42, total tau and phosphorylated tau, the field has evolved to include blood-based assays, neuroimaging ligands and novel molecular signatures derived from extracellular vesicles and multimodal omics. Recent technological advances in proteomics, lipidomics and network analysis have enabled unbiased discovery of candidate markers, while digital health platforms and machine learning facilitate integration of diverse data streams. Standardisation of pre-analytical procedures and validation across cohorts remain critical to translation into clinical practice. The global prevalence of Alzheimer’s disease underscores the need for accessible, cost-effective diagnostics that can guide early intervention and accelerate drug development. Emerging biomarkers show promise in reflecting synaptic integrity, neuroinflammation and protease activity, offering a path towards personalised monitoring and stratified therapeutic strategies.

Research from Nature Portfolio

Recent studies have employed multiscale probabilistic networks built on genomic, transcriptomic and proteomic profiles from patients with Alzheimer’s pathology. These analyses identified the neuropeptide precursor VGF as a high-confidence master regulator of disease networks. Overexpression of VGF in an amyloid mouse model attenuated plaque burden and rescued memory deficits, while downstream gene expression changes validated predicted causal pathways. This work demonstrates the value of integrating multi-omics data to uncover novel targets and mechanistic biomarkers that may inform therapeutic development and early diagnosis.

Biomarker Development for Alzheimer's Disease Diagnostics publication trend

The graph below shows the total number of articles in biomarker development for alzheimer's disease diagnostics across all publications each year (not limited to Nature Index journals).

Technical terms

Biomarker: A measurable biological molecule or process indicating normal or pathological states.

Amyloid-β: A peptide derived from amyloid precursor protein that aggregates into extracellular plaques in Alzheimer’s disease.

Tau protein: A microtubule-associated protein that forms intracellular neurofibrillary tangles when hyperphosphorylated.

Cerebrospinal fluid (CSF): The clear fluid surrounding the brain and spinal cord, used for diagnostic biomarker sampling.

β-Secretase: An enzyme that cleaves amyloid precursor protein to produce amyloid-β peptides.

References

1. The foundation and architecture of precision medicine in neurology and psychiatry. Trends in Neurosciences (2023).
2. Noninvasive Assessment of β‐Secretase Activity Through Click Chemistry‐Mediated Enrichment of Neuronal Extracellular Vesicles to Detect Alzheimer's Disease. Advanced Science (2025).
3. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathologica (2018).
4. Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers. Experimental & Molecular Medicine (2019).
5. Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer’s disease. Alzheimer's Research & Therapy (2018).
6. Isoprostanes and Neuroprostanes as Biomarkers of Oxidative Stress in Neurodegenerative Diseases. Oxidative Medicine and Cellular Longevity (2014).
7. Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease. Nature Communications (2020).